Related Experiment Video
Updated: May 16, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Polymorphisms in genes encoding nonsarcomeric proteins and their role in the pathogenesis of dilated cardiomyopathy
J Staab1, V Ruppert, S Pankuweit
1Department of Psychosomatic Medicine and Psychotherapy, German Centre for Cardiovascular Research, University of Göttingen, Waldweg 33, 37073, Göttingen, Germany.
Insights
Dilated cardiomyopathy (DCM) involves genetic factors and immune responses. A CTLA4 gene variant is linked to DCM, suggesting immune system involvement in heart dysfunction and prompting searches for new genetic markers.
Area of Science:
- Cardiology
- Genetics
- Immunology
Background:
- Dilated cardiomyopathy (DCM) is a heart condition causing heart failure and sudden death.
- Its causes are diverse, including genetic mutations affecting heart muscle structure.
- Autoimmune processes are increasingly recognized as a factor in DCM development.
Purpose of the Study:
- To explore the genetic underpinnings of dilated cardiomyopathy.
- To investigate the role of immune system genes in DCM pathogenesis.
- To highlight the association between CTLA4 gene variants and DCM.
Main Methods:
- Review of existing literature on DCM genetics and autoimmune factors.
- Analysis of studies linking single-nucleotide polymorphisms (SNPs) to DCM.
- Focus on the function of cytotoxic T-lymphocyte antigen 4 (CTLA4) in immune regulation.
Main Results:
- Single-gene mutations in cytoskeletal and sarcomeric proteins are implicated in familial DCM.
- A specific SNP in the CTLA4 gene is associated with DCM diagnosis.
- CTLA4's role as a T-cell regulator suggests immune imbalance contributes to DCM.
Conclusions:
- Genetic factors, including immune-related genes like CTLA4, play a significant role in DCM.
- The findings support the hypothesis that immune dysregulation contributes to left ventricular dysfunction.
- Further research into non-cardiomyocyte genes may uncover novel DCM-associated SNPs.
Abstract:
Dilated cardiomyopathy (DCM), clinically characterized by contractile dysfunction and ventricular chamber enlargement, is a heterogeneous heart disease leading to progressive systolic heart failure and sudden cardiac death. The etiology of the disease is multifactorial and involves genetic factors, viral infections, autoimmune phenomena, and toxic agents. Within the last two decades, a growing body of evidence has suggested that single-gene mutations play a pivotal role in the development of familial forms of dilated cardiomyopathies. Numerous genes encoding cytoskeletal, sarcomeric, and nuclear proteins have been linked to the pathogenesis of DCM, and most of the respective mutants disrupt the structural integrity of sarcomeres in cardiac myocytes. Frequently, point mutations in cytoskeletal proteins critically diminish force generation and interfere with mechanical transduction within the contractile apparatus of the myocardium, thereby ultimately leading to impaired systolic function. However, hitherto reported sarcomeric gene defects explain the etiology of the disease only in some families, leaving other forms of DCM subentities unresolved. Since one of the major factors in DCM pathogenesis involves autoimmune-mediated damage to cardiac tissue, candidate genes that are involved in controlling immune reactions have currently come into focus in genetic research. We and others have shown that a single-nucleotide polymorphism (SNP) in the gene encoding cytotoxic T-lymphocyte antigen 4 (CTLA4) is associated with the diagnosis of DCM. Cytotoxic T-lymphocyte antigen 4 is an inhibitory receptor molecule expressed on activated T lymphocytes, where it functions as an important negative regulator of T-cell activation by competing with the costimulatory CD28 receptor to bind to B7 receptors localized on the surface of antigen-presenting cells. The observed association between CTLA4 genotypes and DCM suggests that genetic factors contribute to both unbalanced immune responses in the myocardium and the development of left ventricular dysfunction. In this review, we will briefly discuss how these findings may stimulate the search for novel DCM-associated SNPs in human genes expressed in noncardiomyocytes.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

